Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $100.00 at Guggenheim

Celldex Therapeutics (NASDAQ:CLDX) had its price target lifted by Guggenheim from $90.00 to $100.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also recently issued reports on CLDX. Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 target price on the stock in a research report on Monday, March 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Friday. HC Wainwright restated a “buy” rating and issued a $42.00 target price on shares of Celldex Therapeutics in a research report on Monday, June 15th. UBS Group upped their price target on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, Wall Street Zen upgraded shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and an average price target of $53.91.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX opened at $35.42 on Monday. Celldex Therapeutics has a 1 year low of $19.72 and a 1 year high of $40.30. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of -8.31 and a beta of 0.90. The company’s 50 day simple moving average is $33.39 and its 200 day simple moving average is $30.47.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.80 million. As a group, analysts anticipate that Celldex Therapeutics will post -4.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new position in Celldex Therapeutics in the 3rd quarter valued at approximately $42,000. Russell Investments Group Ltd. lifted its holdings in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares during the period. Quantbot Technologies LP acquired a new position in shares of Celldex Therapeutics during the third quarter worth $63,000. Kestra Advisory Services LLC bought a new stake in shares of Celldex Therapeutics in the fourth quarter worth $98,000. Finally, Headlands Technologies LLC acquired a new stake in Celldex Therapeutics in the second quarter valued at $125,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.